Development and user insights of a novel real-world treatment registry that combines germline hereditary cancer, tumor mutational landscape, and homologous recombination deficiency data with patient clinical characteristics

Studies that examine the real-world clinical impact of germline hereditary cancer, tumor mutational landscape, and homologous recombination deficiency (HRD) on medical decision making and therapy are lacking. This is potentially due to challenges in compiling structured data from multiple sources outside of clinical trials. To address this need, we created a data-sharing platform from reliable patient datasets that combines germline and tumor genetic test results, family history, management, and outcomes. Here, we described the structure and composition of this registry and initial user interest.